Current status of treatment and disease burden of a cohort of hemophilia B in China
Yiwen Huang, Chuchuan Wan, Tao Guan, Xiaoyu Xi · 2024
Read Current status of treatment and disease burden of a cohort of hemophilia B in China by Yiwen Huang, Chuchuan Wan, Tao Guan, Xiaoyu Xi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10847226.txt.
Description
Yiwen Huang and co-authors present a study of care and cost for hemophilia B in China, a rare inherited bleeding disorder. Patients need clotting factor for life, and care is dear. The team used data from a Beijing care centre covering several hundred patients.
About a third got treatment only when bleeds struck. The rest got some preventive dosing, at varied levels. Drug costs for the group topped a large yearly sum, and preventive care cost far more than on-demand care. An older, less pure product dominated use. Lost wages added a heavy load, and most patients reported chronic or acute pain. The authors urge wider access to safer drugs and lower costs.
Catalog record
| CREATOR | Yiwen Huang, Chuchuan Wan, Tao Guan, Xiaoyu Xi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |